JPRN-UMIN000028000
Recruiting
Phase 2
A phase 2 study of transcatheter aterial chemoembolization using cisplatin and DC beads for advanced hepatocellular carcinoma - DEB-TACE(CDDP+DC beads)
ational Hospital Organization KURE Medical Center0 sites30 target enrollmentAugust 1, 2017
ConditionsHCC
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- HCC
- Sponsor
- ational Hospital Organization KURE Medical Center
- Enrollment
- 30
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •(1\)HCC without stain on angiogram. (2\)History of hypersensitivity to cisplatinum\-containing drug. (3\)distant metastasis (4\)main portal tumor thrombosis or hepatic vein tumor thrombosis (5\)Patients with intrahepatic AP shunt or AV shunt. (6\)Patients with complications to be treated preferentially. (7\)Patients who can not keep their rest during the procedure. (8\)Patients who are concluded to be inappropriate to participate in this study by their physicians.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 1
Phase I/II study of transcatheter arterial chemo-embolization with DDP-H and degradable starch microspheres for hepatic metastases of colorectal cancerColorectal CancerJPRN-UMIN000001168Radiology, Nara Medical University Hospital27
Completed
Phase 2
PhaseII study of trancatheter arterial chemoembolizaion with miriplatin for hepatocellular carcinoma -Compared with retrospective historical cohort study with epirubicin hydrochlorideJPRN-UMIN000005229ara Medical University, Department of Radiology33
Completed
Not Applicable
A phase I/II study of transarterial chemoembolization with cisplatin for hepatocellular carcinoma (JIVROSG-0401)nresectable hypervascular hepatocellular carcinomaJPRN-C000000049Japan Interventional Radiology in Oncology Study Group (JIVROSG)60
Completed
Phase 2
Phase II study: Transcatheter Arterial Chemoembolization Therapy In Combination with Sorafenib (TACTICS)HCCJPRN-UMIN000004316Japan Liver Oncology Group228
Active, not recruiting
Not Applicable
Phase II study evaluating transarterial chemoembolization (TACE) in combination with sorafenib for the treatment of advanced hepatocellular carcinoma (HCC) - TACE and sorafenib for HCChistologically proven advanced hepatocellular carcinoma (HCC) not suitable for resection or liver transplantation but without extrahepatic manifestations and without previous treatment for HCCMedDRA version: 9.1Level: LLTClassification code 10019828Term: Hepatocellular carcinoma non-resectableEUCTR2007-000730-40-DEHeinrich-Heine-Universität Düsseldorf